{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T01:17:15Z","timestamp":1770081435290,"version":"3.49.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,23]]},"DOI":"10.7759\/cureus.62957","type":"journal-article","created":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T13:36:16Z","timestamp":1719149776000},"source":"Crossref","is-referenced-by-count":2,"title":["Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors and the Risk of Pancreatitis: A Case Report"],"prefix":"10.7759","author":[{"given":"Zamanali","family":"Khakhar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soraiya","family":"Manji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronak Kumar","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayed K","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/676191","article-title":"Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient","volume":"2015","author":"Bell DS","year":"2015","unstructured":"Bell DS. Case reports that illustrate the efficacy of SGLT2 inhibitors in the type 1 diabetic patient. Case Rep Endocrinol. 2015, 2015:676191. 10.1155\/2015\/676191","journal-title":"Case Rep Endocrinol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jash.2014.02.003","article-title":"Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors","volume":"8","author":"Oliva RV","year":"2014","unstructured":"Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens. 2014, 8:330-9. 10.1016\/j.jash.2014.02.003","journal-title":"J Am Soc Hypertens"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-real 2 study","author":"Kosiborod M","year":"2018","unstructured":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs. the CVD-real 2 study. 2018, 71:2628-39. 10.1016\/j.jacc.2018.03.009"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.121.17005","article-title":"Cardiovascular protection with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in chronic kidney disease: a milestone achieved","volume":"77","author":"Sarafidis P","year":"2021","unstructured":"Sarafidis P, Papadopoulos CE, Kamperidis V, Giannakoulas G, Doumas M. Cardiovascular protection with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in chronic kidney disease: a milestone achieved. Hypertension. 2021, 77:1442-55. 10.1161\/HYPERTENSIONAHA.121.17005","journal-title":"Hypertension"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/1479164114559852","article-title":"SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials","volume":"12","author":"Inzucchi SE","year":"2015","unstructured":"Inzucchi SE, Zinman B, Wanner C, et al.. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diab Vasc Dis Res. 2015, 12:90-100. 10.1177\/1479164114559852","journal-title":"Diab Vasc Dis Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i22.2902","article-title":"Ever-increasing diversity of drug-induced pancreatitis","volume":"26","author":"Weissman S","year":"2020","unstructured":"Weissman S, Aziz M, Perumpail RB, Mehta TI, Patel R, Tabibian JH. Ever-increasing diversity of drug-induced pancreatitis. World J Gastroenterol. 2020, 26:2902-15. 10.3748\/wjg.v26.i22.2902","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2020.07.401","article-title":"Drug-induced acute pancreatitis: Prevalence, Causative agents, and Outcomes","volume":"20","author":"Chadalavada P","year":"2020","unstructured":"Chadalavada P, Simons-Linares CR, Chahal P. Drug-induced acute pancreatitis: Prevalence, Causative agents, and Outcomes. Pancreatology. 2020, 20:1281-6. 10.1016\/j.pan.2020.07.401","journal-title":"Pancreatology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2010.02.002","article-title":"Drug induced pancreatitis","volume":"24","author":"Nitsche CJ","year":"2010","unstructured":"Nitsche CJ, Jamieson N, Lerch MM, Mayerle JV. Drug induced pancreatitis. Best Pract Res Clin Gastroenterol. 2010, 24:143-55. 10.1016\/j.bpg.2010.02.002","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.49369","article-title":"A rare case of sodium-glucose cotransporter-2 inhibitor-induced acute pancreatitis","volume":"15","author":"Haddadin R","year":"2023","unstructured":"Haddadin R, Tonna RF, Iqbal H, Valenta J, Iraninezhad H. A rare case of sodium-glucose cotransporter-2 inhibitor-induced acute pancreatitis. Cureus. 2023, 15:e49369. 10.7759\/cureus.49369","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.5530\/ijmedph.2018.1.10","article-title":"Dapagliflozin induced pancreatitis","volume":"8","author":"Gutch M","year":"2018","unstructured":"Gutch M, Bhattacharya A, Kumar S, Pahan RK, Singh RS. Dapagliflozin induced pancreatitis. Int J Med Public Health. 2018, 8:45-7.","journal-title":"Int J Med Public Health"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/6724504","article-title":"Dapagliflozin-induced acute pancreatitis: a case report and review of literature","volume":"2020","author":"Sujanani SM","year":"2020","unstructured":"Sujanani SM, Elfishawi MM, Zarghamravanbaksh P, Castillo FJ, Reich DM. Dapagliflozin-induced acute pancreatitis: a case report and review of literature. Case Rep Endocrinol. 2020, 2020:6724504. 10.1155\/2020\/6724504","journal-title":"Case Rep Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231883","article-title":"Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations","volume":"15","author":"Wolfe D","year":"2020","unstructured":"Wolfe D, Kanji S, Yazdi F, et al.. Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations. PLoS One. 2020, 15:e0231883. 10.1371\/journal.pone.0231883","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.977582","article-title":"Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on Food and Drug Administration adverse event report system database","volume":"13","author":"Zhang L","year":"2022","unstructured":"Zhang L, Mao W, Li X, Wang X, Liu J, Hu S, Hu J. Analysis of acute pancreatitis associated with SGLT-2 inhibitors and predictive factors of the death risk: Based on Food and Drug Administration adverse event report system database. Front Pharmacol. 2022, 13:977582. 10.3389\/fphar.2022.977582","journal-title":"Front Pharmacol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.25189","article-title":"Empagliflozin-induced pancreatitis: A case report pattern","volume":"14","author":"Foster P","year":"2022","unstructured":"Foster P, Jha P, Pandit S. Empagliflozin-induced pancreatitis: A case report pattern. Cureus. 2022, 14:e25189. 10.7759\/cureus.25189","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/262944-sodium-glucose-transport-protein-2-sglt2-inhibitors-and-the-risk-of-pancreatitis-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T13:36:19Z","timestamp":1719149779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/262944-sodium-glucose-transport-protein-2-sglt2-inhibitors-and-the-risk-of-pancreatitis-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,23]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.62957","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,23]]}}}